Diversa Signs Agreement with GlaxoSmithKline to Advance Development of a Novel Anti-Infective Compound
Diversa Corporation announced that it has signed an agreement with GlaxoSmithKline to advance the development of an anti-infective compound initially discovered by GSK. This agreement represents an innovative approach to leverage and integrate core capabilities in process development and drug development of the respective companies to advance a novel anti-infective compound.
Under the terms of this agreement, Diversa will have the primary responsibility to develop the chemistry processes required to advance the compound into clinical development. Upon achievement of specific performance criteria by Diversa, GSK will have the option to further develop this compound and obtain exclusive worldwide commercialization rights in exchange for milestone payments, option and license fees, and royalties to Diversa. If GSK decides not to exercise this option, then Diversa will obtain development and commercialization rights to the compound in exchange for royalties to GSK.
"We look forward to working on this important anti-infective compound, which is complementary with our anti-infective focus and our strategy of pursuing therapeutics to treat serious, hospital-based infections," said Dr. Jay M. Short, Diversa's President and Chief Executive Officer.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.